Last Updated : May 14, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
---|---|---|---|---|---|---|
N/A | Nivolumab and Ipilimumab | Melanoma (Skin) | Active | |||
Tafinlar-Mekinist | dabrafenib trametinib | Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation | Pending | |||
TBC | danicopan | Paroxysmal nocturnal hemoglobinuria (PNH) | Active | |||
Vabysmo | faricimab | Retinal vein occlusion | Pending | |||
Olumiant | baricitinib | Alopecia areata, severe | Active | |||
Trikafta | elexacaftor/tezacaftor/ivacaftor and ivacaftor | Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older | Active | |||
TBC | ivosidenib | Acute myeloid leukemia (AML) | Active | |||
Keytruda | pembrolizumab | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Active | |||
N/A | nab-paclitaxel | Gastrointestinal cancer | Pending | |||
Remsima | Infliximab | Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis | Withdrawn |